The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCAT 2023 | An update on the treatment of SCD
Lewis Hsu, MD, PhD, University of Illinois Chicago, Chicago, IL, discusses the exciting progress in sickle cell disease (SCD) treatment, generating enthusiastic anticipation within the community. The development of several cutting-edge gene therapies holds the potential for curative treatment and an improvement in quality of life of patients. They will come under FDA approval review before the end of 2023. This interview was recorded at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
